Graham McCain · Alphaforge Research · Published Sep 18, 2026 · 4:18 pm ET · Revision 2 Scored over 5 trading sessions.
AI summary
Xenon filed its NDA for azetukalner in focal seizures and paused new enrollment in its depression and bipolar studies due to neuropsychiatric adverse events not seen in earlier trials. The stock closed Thursday at $57.35 and was trading premarket at $44.27, a drop of 23%. The note views the market as acting like the psychiatry program is being written off, leaving only the epilepsy filing.
The note's historical data, based on 300 analogous states, shows a typical five-session excess return range from a low of -7.2% to a high of +7.9%. The strongest counterpoint is that the NDA submission was expected and the company has substantial cash. The first checkpoint to watch is the closing price from the first full session after the news, which was September 18.
Two paragraphs generated from the note. The authored note below is the record. Numbers only, no side.
1. The state
As of the 2026-09-17 close. Session 1 has closed.
Xenon closed the September 17 regular session at $57.35, up 1.0% from Wednesday's $56.76, on 1.79 million shares, about 2.9 times the 20-day average, 21% below the 52-week high of $72.66 on July 9. Premarket at 09:08 ET the last print was $44.27, 22.8% below that close.
2. What's new
GlobeNewswire at 16:01 ET September 17: NDA for azetukalner in focal seizures submitted; voluntary pause on new psychiatry enrollment after neuropsychiatric AEs not seen in Phase 2 X-NOVA; X-NOVA2 about 360 of 450, topline now Q1 2027.
3. What that does to the state
The tape is acting as if the psychiatry option is being written off and the epilepsy NDA is what remains.
No comparison is ready for XENE on this session yet. Either that day's data is not in, or this name is too thinly traded for a comparison. If the note cites an earlier close, that is the last built range.
4. Same state, or a new one
No analog band this clock
Session 1 vs the market: -30.6. No prior-state range on this clock, so we cannot say stayed or left.
XENE closed at $39.75, -30.7% versus the $57.35 close of 2026-09-17, on 17.8 million shares, about 26.3 times the 20-day average; the session's range was $39.08 to $44.85 after a $44.02 open. Against the market (SPY -0.1%), the excess move was -30.6 points.
This reading is wrong if Friday's regular close holds most of the overnight gap, or a later filing or FDA action hits the epilepsy program rather than only psychiatry enrollment.
Session 1: -30.6, no band. Session 5: -34.2, no band. Session 10: -32.3, no band. Scorecard
When we look again
Session 1: September 18 close. Session 5: September 25. Session 10: October 2. Company: X-NOVA2 topline, now Q1 2027; FDA filing clock on the focal-seizure NDA.
Xenon closed Thursday at $57.35, up 1.0% from Wednesday's $56.76, 21% under the July 9 high of $72.66. The largest completed one-day drop in 90 sessions was 4.2% on August 20. At 16:01 ET it put out a company release: the NDA for azetukalner in focal seizures is in, and new enrollment in the depression and bipolar studies is paused after neuropsychiatric adverse events that were not seen in Phase 2 X-NOVA. Premarket at 09:08 ET the last print was $44.27, 23% below that close. On 96.8 million shares that is about $1.3 billion of equity, next to $1.25 billion of cash at June 30.
The NDA is the third-quarter filing they said they would make. It sits on X-TOLE and X-TOLE2. Epilepsy studies keep enrolling. The pause is psychiatry: X-NOVA2 is about 360 of 450 patients, enough they say to unblind; topline now Q1 2027. Enrolled patients stay on drug. They will look at dose. No 8-K is on EDGAR this morning.
The tape is acting as if psychiatry was a large part of the $5.55 billion close. The overnight print is already larger than the 1-day neighborhood of that quiet close (p10 −3.2). Friday's regular session is the first score. We do not have a new band until that session completes.
Other reading, tape, and sources
The other reading
The NDA is in, the epilepsy program has more than 1,500 patient-years of safety, and cash funds operations into 2029. If Friday fills most of the gap with no further safety disclosure, the pause was a caption on a filing they already said they would make.
What would change this
This reading is wrong if Friday's regular close holds most of the overnight gap, or a later filing or FDA action hits the epilepsy program rather than only psychiatry enrollment.
The tape
Xenon closed the September 17 regular session at $57.35, up 1.0% from Wednesday's $56.76, on 1.79 million shares, about 2.9 times the 20-day average, 21% below the 52-week high of $72.66 on July 9. Premarket at 09:08 ET the last print was $44.27, 22.8% below that close.
What was filed
GlobeNewswire at 16:01 ET September 17: NDA for azetukalner in focal seizures submitted; voluntary pause on new psychiatry enrollment after neuropsychiatric AEs not seen in Phase 2 X-NOVA; X-NOVA2 about 360 of 450, topline now Q1 2027. Epilepsy studies continue. No Form 8-K is on EDGAR for this release. The 16:30 ET call was not heard as a primary. Not checked: issuer IR index and presentations as a live machine source. The issuer press-release index and investor presentation pages were not reachable at check time; this note uses GlobeNewswire and EDGAR.
The numbers around the move
The tape is acting as if the psychiatry option is being written off and the epilepsy NDA is what remains. The 5-session band on the September 16 close is −7.2 / −0.5 / +7.9. A 23% overnight print is not that neighborhood; it is a candidate new state, not a new band.
What the stock did
Not yet observed as a completed session after the release. The September 17 regular close was $57.35, +1.0% versus Wednesday, before the 16:01 ET company print. Premarket at 09:08 ET the last print was $44.27.
Close update, session 1 (September 18, written after the close): XENE closed at $39.75, -30.7% versus the $57.35 close of 2026-09-17, on 17.8 million shares, about 26.3 times the 20-day average; the session's range was $39.08 to $44.85 after a $44.02 open. Against the market (SPY -0.1%), the excess move was -30.6 points. Against the 1h band of what followed similar states as of the September 16 close (the last built clock; p10 −3.2, median 0.0, p90 +3.2), this session left that neighborhood (below the quiet tail). An abnormal follow-through for that state — look at what changed — not a miss by the memory. Friday's regular close is session 1; the Thursday after-hours print is not. The September 17 identity is still not built, so this is not a new band.
The comparison
The latest built state is the September 16 close: 300 analogous states across 178 symbols. Five-session excess: p10 −7.2 / median −0.5 / p90 +7.9, up 44% of the time. Measured before the release. The September 17 identity is not built.
Sources
Read the September 17 GlobeNewswire release, the August 6 Q2 Exhibit 99.1 (cash $1,245.1 million, 96,752,884 common shares), EDGAR submissions through this morning (no September 17 8-K), Yahoo daily and premarket bars, and the Chart Library packet for the September 16 close. The September 17 state identity is not built. The 16:30 ET company call was not heard as a primary. Issuer press-release and presentation pages were not in the scanner until this morning; this note uses the GlobeNewswire text and EDGAR. A dated contributor-level consensus was not retrieved. Sell-side target cuts overnight are secondary reports of notes we have not read.
Live situations, scored after the close. Not a buy list.
The daily note is free and stays free. Follow @ChartLibraryio.
Publication history
Revision 1 · Sep 18, 2026 · 9:15 am ET · Initial publication
Revision 2 · Sep 18, 2026 · 4:18 pm ET · Close update, session 1: completed session versus the framing and the analog band
AI-assisted drafting from the company release, the Q2 exhibit, EDGAR submissions, Yahoo bars and Chart Library's state memory; sources and arithmetic checked by the author.
